AU1286399A - 3-aminoalkylamino- 2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands - Google Patents

3-aminoalkylamino- 2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands

Info

Publication number
AU1286399A
AU1286399A AU12863/99A AU1286399A AU1286399A AU 1286399 A AU1286399 A AU 1286399A AU 12863/99 A AU12863/99 A AU 12863/99A AU 1286399 A AU1286399 A AU 1286399A AU 1286399 A AU1286399 A AU 1286399A
Authority
AU
Australia
Prior art keywords
aminoalkylamino
benzothiazines
benzoxazines
dopamine receptor
receptor subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12863/99A
Inventor
Xiao-Shu He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of AU1286399A publication Critical patent/AU1286399A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU12863/99A 1997-10-31 1998-10-28 3-aminoalkylamino- 2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands Abandoned AU1286399A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96202297A 1997-10-31 1997-10-31
US08962022 1997-10-31
PCT/US1998/022936 WO1999023092A2 (en) 1997-10-31 1998-10-28 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
AU1286399A true AU1286399A (en) 1999-05-24

Family

ID=25505330

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12863/99A Abandoned AU1286399A (en) 1997-10-31 1998-10-28 3-aminoalkylamino- 2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands

Country Status (5)

Country Link
EP (1) EP1027347A2 (en)
JP (1) JP2001521935A (en)
AU (1) AU1286399A (en)
CA (1) CA2307905A1 (en)
WO (1) WO1999023092A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100255A (en) * 1998-10-28 2000-08-08 Neurogen Corporation 3-aminoalkylamino-2H-1,4-benzoxazines and 3-aminoalkylamino-2H-1,4-benzothiazines: dopamine receptor subtype specific ligands
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
CA2321830A1 (en) * 1998-02-26 1999-09-02 Neurogen Corporation Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d4 receptor antagonists
CN1325397A (en) * 1998-09-30 2001-12-05 纽罗根公司 2-piperazino alkylatnino benzoazole derivatives: dopamine receptor subtype sepcific ligands
US6284759B1 (en) 1998-09-30 2001-09-04 Neurogen Corporation 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands
DE19941115A1 (en) * 1999-08-25 2001-03-01 Schering Ag New benzoxazine and bezothiazine derivatives and their use in drugs
EP1177792A3 (en) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
US8411271B2 (en) 2005-12-28 2013-04-02 Nikon Corporation Pattern forming method, pattern forming apparatus, and device manufacturing method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186310A1 (en) * 1984-11-28 1986-07-02 Takeda Chemical Industries, Ltd. 1,4-Benzothiazine Derivatives, their production and use

Also Published As

Publication number Publication date
EP1027347A2 (en) 2000-08-16
JP2001521935A (en) 2001-11-13
WO1999023092A3 (en) 1999-08-05
CA2307905A1 (en) 1999-05-14
WO1999023092A2 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
HUP9901436A3 (en) N-aminoalkylfluorenecarboxamides as dopamine receptor subtype ligands
AU4057097A (en) Fused indolecarboxamides: dopamine receptor subtype specific ligands
AU4802500A (en) 2-aminoquinolinecarboxamides: neurokinin receptor ligands
ZA9610738B (en) Subtype selective nmda receptor ligands and the use thereof
PL353969A1 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands
AU1199600A (en) Estrogen receptor ligands
AU8096798A (en) Dopamine d4 receptor ligands
AU3592095A (en) Eph receptor ligands, and uses related thereto
AU4217299A (en) Pth1r and pth3r receptors, methods and uses thereof
AU1191001A (en) Plasminogen-like polynucleotides, polypeptides, and antibodies
AU5319700A (en) Nicotine receptor ligands
AU2738297A (en) Tricyclic aminoalkylcarboxamides; novel dopamine d3 receptor subtype specific ligands
AU7132898A (en) Edg-1-like receptor
HK1038749A1 (en) 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
AU1582401A (en) Uteroglobin-like polynucleotides, polypeptides, and antibodies
AU8743098A (en) Benzothiadiazinyl-indole derivatives and their use as serotonin receptor ligands
AU7335400A (en) Attractin-like polynucleotides, polypeptides, and antibodies
AU1286399A (en) 3-aminoalkylamino- 2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands
AU3632297A (en) Spirocyclic dopamine receptor subtype ligands
AU6913100A (en) Notch receptor ligands and uses thereof
GB9704376D0 (en) Tetrahydropyridine derivatives as dopamine receptor subtype ligands
AU1744700A (en) Human neurotensin subtype 2 receptor
AU2459597A (en) N-aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
AU6230698A (en) Dopamine d4 receptor antagonist
AU2335797A (en) Novel n-aminoalkyl-2-anthracenecarboxamides; new dopamine receptor subtype specific ligands

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase